Pharmacology of the antifungals used in the treatment of aspergillosis
Azanza JR (1), Sádaba B (2), Gómez-Guíu A (2).
(1) Servicio de Farmacología Clínica, Clínica universidad de Navarra, Pamplona, España.
(2) Servicio de Farmacología Clínica, Clínica universidad de Navarra, Pamplona, España.
The treatment of invasive aspergillosis requires the use of drugs that characteristically have complex pharmacokinetic properties, the knowledge of which is essential to achieve maximum efficacy with minimal risk to the patient.
The lipid-based amphotericin B formulations vary significantly in their pharmacokinetic behaviour, with very high plasma concentrations of the liposomal form, probably related to the presence of cholesterol in their structure. Azoles have a variable absorption profile, particularly in the case of itraconazole and posaconazole, with the latter very dependent on multiple factors. This may also lead to variations in voriconazole, which requires considering the possibility of monitoring plasma concentrations.
The aim of this article is to review some of the most relevant aspects of the pharmacology of the antifungals used in the prophylaxis and treatment of the Aspergillus infection. For this reason, it includes the most relevant features of some of the azoles normally prescribed in this infection (itraconazole, posaconazole and voriconazole) and the amphotericin B formulations.
CITATION Rev Iberoam Micol. 2014 Oct-Dec;31(4):255-61. doi: 10.1016/j.riam.2014.05.001